Newsroom

Sorted by: Latest

-

NRIM Stock Alert: Halper Sadeh LLC is Investigating Whether Northrim BanCorp, Inc. is Obtaining a Fair Price for its Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Northrim BanCorp, Inc. (NASDAQ: NRIM) and PBCO Financial Corporation.Halper Sadeh encourages Northrim shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.The investigation concerns whether Northrim and its board of directors violated the federal se...
-

BLFS Stock Alert: Halper Sadeh LLC is Investigating Whether BioLife Solutions, Inc. is Obtaining a Fair Price for its Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of BioLife Solutions, Inc. (NASDAQ: BLFS) to Repligen Corporation for $11.25 per share in cash and 0.1442 shares of Repligen common stock.Halper Sadeh encourages BioLife shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.The investigation concerns whet...
-

XTIA CLASS ACTION NOTICE: The Law Offices of Frank R. Cruz Files Securities Fraud Lawsuit Against XTI Aerospace, Inc.

LOS ANGELES--(BUSINESS WIRE)--XTIA CLASS ACTION NOTICE: The Law Offices of Frank R. Cruz Files Securities Fraud Lawsuit Against XTI Aerospace, Inc....
-

Destiny Tech100 Inc. Reports Second Quarter 2026 Results

NEW YORK--(BUSINESS WIRE)--Destiny Tech100 Inc. (NYSE: DXYZ) today announced financial results for the quarter ended June 30, 2026. The fund reported a net asset value (NAV) of $34.30 per share of common stock, up from $24.56 per share at the end of the first quarter of 2026.As of June 30, 2026, Destiny Tech100’s investment portfolio had an aggregate fair value of approximately $1.64 billion, including short-term investments. The fund maintains positions in a variety of privately-held technology...
-

XTIA CLASS ACTION NOTICE: Glancy Prongay Wolke & Rotter LLP Files Securities Fraud Class Action Lawsuit on Behalf of XTI Aerospace, Inc. Investors

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP (“GPWR”), announces that it has filed a class action lawsuit in the United States District Court for the Southern District of New York, captioned Noalan v. XTI Aerospace, Inc. et al., Case No. 26-cv-07378, on behalf of persons and entities that purchased or otherwise acquired XTI Aerospace, Inc. (“XTI Aerospace” or the “Company”) (NASDAQ: XTIA) securities between April 15, 2026 and August 17, 2026, inclusive (the “Class Period”)...
-

INV CLASS ACTION NOTICE: Glancy Prongay Wolke & Rotter LLP Files Securities Fraud Class Action Lawsuit On Behalf of Innventure, Inc. Investors

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP (“GPWR”), announces that it has filed a class action lawsuit in the United States District Court for the Southern District of New York, captioned Labed v. Innventure, Inc. et al., Case No. 26-cv-07377, on behalf of persons and entities that purchased or otherwise acquired Innventure, Inc. (“Innventure” or the “Company”) (NASDAQ: INV) securities between November 17, 2025 and August 13, 2026, inclusive (the “Class Period”). Plaint...
-

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total...
-

Rigaku et l’université de Tohoku créent un nouvel institut de recherche dédié à la métrologie par rayons X

TOKYO--(BUSINESS WIRE)--Rigaku Corporation, filiale de Rigaku Holdings et un partenaire mondial spécialisé dans les solutions pour systèmes d’analyse par rayons X (siège social : Akishima, Tokyo ; PDG : Jun Kawakami ; ci-après « Rigaku »), et l’Université de Tohoku (Sendai, préfecture de Miyagi ; président : Teiji Tominaga ; ci-après « l’Université de Tohoku ») ont créé, le 1er août 2026, le Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology : Beyond The Limits (ci-aprè...
-

Innolitics and BEACON-Neuro.AI Partner to Bring FDA Breakthrough Device BEACONPredict to Market

SAN FRANCISCO--(BUSINESS WIRE)--Innolitics, a medical-device software and FDA regulatory services provider, and BEACON-Neuro.AI Inc., a Washington University in St. Louis startup, today announced the partnership behind BEACONPredict, AI software for predicting malignant cerebral edema risk after acute ischemic stroke. Innolitics brought the regulatory strategy and software engineering; BEACON-Neuro.AI brought the clinical science out of Dr. Raj Dhar's neurocritical-care lab at WashU Medicine. T...
-

Rigaku y la Universidad de Tohoku crean un nuevo instituto de investigación dedicado a la metrología por rayos X

TOKIO--(BUSINESS WIRE)--Rigaku Corporation, empresa del grupo Rigaku Holdings especializada en soluciones de análisis por rayos X a nivel mundial (sede central: Akishima, Tokio; presidente y director ejecutivo: Jun Kawakami; en adelante, «Rigaku»), y la Universidad de Tohoku (Sendai, Miyagi; presidente: Teiji Tominaga; en adelante, «Universidad de Tohoku») crearon el Instituto de Investigación Conjunta Rigaku–Universidad de Tohoku para la metrología por rayos X: Beyond The Limits (el «Instituto...